Literature DB >> 7523409

Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas.

E P Garvey1, J A Oplinger, G J Tanoury, P A Sherman, M Fowler, S Marshall, M F Harmon, J E Paith, E S Furfine.   

Abstract

S-Ethylisothiourea was a potent competitive inhibitor of human nitric oxide synthase (NOS), with Ki values of 17, 36, and 29 nM for the inducible (i), endothelial (e), and neuronal (n) isozymes, respectively. Unlike some potent inhibitors of NOS, no time dependence was observed. S-Ethylisothiourea was not a detectable substrate for eNOS. S-Ethylisothiourea was also a potent inhibitor of mouse iNOS (Ki value of 5.2 nM), and its binding perturbed the spectrum of iNOS consistent with its altering the environment of the bound heme. The optimum binding of S-ethyl- and S-isopropylisothiourea relative to 70 other analogs suggested that these alkyl substitutions fit into a small hydrophobic pocket. Most isothioureas were 2-6-fold selective for the human iNOS (Ki for iNOS versus Ki for eNOS), with one being 19-fold selective. The cyclized mimics of S-ethylisothiourea, 2-NH2-thiazoline, and 2-NH2-thiazole, were also competitive inhibitors of human NOS. A third structural class of inhibitors, bisisothioureas, were, in general, the most selective in their inhibition of human iNOS. S,S'-(1,3-Phenylenebis(1,2-ethanediyl))bisisothiourea was 190-fold selective (Ki value of 0.047 microM against iNOS versus 9.0 microM against eNOS). These results demonstrate that potent and selective inhibition of human NOS isozymes is achievable.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523409

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Comparison of methods for analyzing kinetic data from mechanism-based enzyme inactivation: application to nitric oxide synthase.

Authors:  T Maurer; H L Fung
Journal:  AAPS PharmSci       Date:  2000

2.  Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase- and soluble guanylate cyclase-dependent mechanisms.

Authors:  E Wang; Yan Feng; Ming Zhang; Lin Zou; Yan Li; Emmanuel S Buys; Peigen Huang; Peter Brouckaert; Wei Chao
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

3.  The selenium analog of the chemopreventive compound S,S'-(1,4-phenylenebis[1,2-ethanediyl])bisisothiourea is a remarkable inducer of apoptosis and inhibitor of cell growth in human non-small cell lung cancer.

Authors:  Arunangshu Das; James Bortner; Dhimant Desai; Shantu Amin; Karam El-Bayoumy
Journal:  Chem Biol Interact       Date:  2009-03-20       Impact factor: 5.192

4.  Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide.

Authors:  Yun Wang; Arthur F Monzingo; Shougang Hu; Tera H Schaller; Jon D Robertus; Walter Fast
Journal:  Biochemistry       Date:  2009-09-15       Impact factor: 3.162

Review 5.  The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18-20 March 1995.

Authors:  M P Fink; D Payen
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

6.  Mutation of Glu-361 in human endothelial nitric-oxide synthase selectively abolishes L-arginine binding without perturbing the behavior of heme and other redox centers.

Authors:  P F Chen; A L Tsai; V Berka; K K Wu
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

Review 7.  Cysteine-mediated redox signaling: chemistry, biology, and tools for discovery.

Authors:  Candice E Paulsen; Kate S Carroll
Journal:  Chem Rev       Date:  2013-03-20       Impact factor: 60.622

8.  Spontaneous rearrangement of aminoalkylisothioureas into mercaptoalkylguanidines, a novel class of nitric oxide synthase inhibitors with selectivity towards the inducible isoform.

Authors:  G J Southan; B Zingarelli; M O'Connor; A L Salzman; C Szabó
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

9.  Inhibition by tetranactin of interleukin 1 beta- and cyclic AMP-induced nitric oxide synthase expression in rat renal mesangial cells.

Authors:  D Kunz; G Walker; I Wiesenberg; J Pfeilschifter
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 10.  iNOS: a potential therapeutic target for malignant glioma.

Authors:  A Jahani-Asl; A Bonni
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.